Adv Ther (2017) 34:1989–2006 DOI 10.1007/s12325-017-0582-z ORIGINAL RESEARCH Burden of Atopic Dermatitis in the United States: Analysis of Healthcare Claims Data in the Commercial, Medicare, and Medi-Cal Databases . . . . Sulena Shrestha Raymond Miao Li Wang Jingdong Chao Huseyin Yuce Wenhui Wei Received: April 26, 2017 / Published online: July 13, 2017 The Author(s) 2017. This article is an open access publication Medi-Cal (n = 5550) databases were matched ABSTRACT (1:1) to non-AD controls by demographic char- acteristics. AD patients were stratiﬁed by disease Introduction: Comparative data on the burden of severity (higher, lower) using treatment as a atopic dermatitis (AD) in adults relative to the gen- surrogate measure of severity. The comorbidity eral population are limited. We performed a lar- burden, HCRU, and costs were evaluated during ge-scale evaluation of the burden of disease among a 12-month follow-up period. US adults with AD relative to matched non-AD Results: In the Commercial, Medicare, and controls, encompassing comorbidities, healthcare Medi-Cal populations, patients with AD had a resource utilization (HCRU), and costs, using signiﬁcantly higher overall comorbidity burden healthcare claims data. The impact of AD disease (P\0.0001), an increased risk of asthma and severity on these outcomes was also
Advances in Therapy – Springer Journals
Published: Jul 13, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera